India Providers

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five

11/2/2026, 3:22:05 PM

Share:WhatsApp Facebook X (Twitter)Telegram

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five — Photo / Coverage: The Hindu Business Line

EXECUTIVE SUMMARY

The government regulates the prices of certain medicines to prevent companies from charging patients more than the permitted amount

Key Takeaways

Cipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five.

The government regulates the prices of certain medicines to prevent companies from charging patients more than the permitted amount

Share:WhatsApp Facebook X (Twitter)Telegram

Read Complete Original Article

Published originally on The Hindu Business Line

Visit Publisher Site →

Related News

🇮🇳 India

Economy & Business31m ago

Pocket

Pocket....

The Hindu Business Line

Economy & Business32m ago

Letters to Editor

Letters to Editor....

The Hindu Business Line

Economy & Business32m ago

TRAI amends consumer redressal framework with fine up to ₹20 lakh per quarter per service area for telcos

The amended regulations will apply to ISPs having more than 10,000 subscribers as of the last day of the preceding financial year

The Hindu Business Line

Economy & Business34m ago

GRAP 2 in Delhi: What's allowed; what is not? Which cars, vehicles are banned? Check list before going to office

Delhi-NCR has moved to GRAP Stage II after air quality reached the very poor category, triggering measures to curb pollution. Separately, non-BS-VI petrol and diesel vehicles registered outside Delhi are barred from entering the capital until January 31, 2027.

Livemint - News

Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!